Recent Finacing
Recent Raise
Design Therapeutics develops GeneTAC small molecules that modulate transcription to turn specific genes on/off for nucleotide repeat expansion disorders, advancing Friedreich ataxia and myotonic dystrophy programs toward clinical development.
